Tyra Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TYRA Nasdaq 2836 tyra.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tyra Biosciences, Inc.

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - Jun 30th, 2025 6:00 am
Tyra Biosciences to Participate at Upcoming Investor Conferences - May 12th, 2025 2:05 pm
One Tyra Biosciences Insider Raised Stake By 284% In Previous Year - May 9th, 2025 4:26 am
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights - May 8th, 2025 2:05 pm
Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth - Mar 29th, 2025 7:37 am
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - Mar 27th, 2025 2:05 pm
Tyra Biosciences to Present at Upcoming Investor Conferences - Feb 11th, 2025 2:05 pm
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors - Jan 29th, 2025 2:05 pm
Private equity firms account for 44% of Tyra Biosciences, Inc.'s (NASDAQ:TYRA) ownership, while institutions account for 33% - Jan 27th, 2025 6:53 am
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium - Jan 22nd, 2025 6:00 am
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) - Jan 10th, 2025 6:00 am
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Could Be 43% Below Their Intrinsic Value Estimate - Nov 30th, 2024 7:58 am
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - Nov 7th, 2024 2:05 pm
Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares - Nov 3rd, 2024 6:45 am
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - Oct 28th, 2024 5:00 am
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - Oct 24th, 2024 4:05 pm
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET - Oct 23rd, 2024 2:05 pm
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation - Oct 20th, 2024 7:00 am
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug - Oct 18th, 2024 12:34 pm
Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc - Oct 15th, 2024 11:01 pm